Skip to content

Dr Hannah Moody

Assistant Professor

Faculty/Dept/School School of Pharmacy and Medical Sciences
(Faculty of Life Sciences)
Telephone +441274 238459


Dr Hannah Moody is a Lecturer in Cell and Molecular Biology at the University of Bradford.

Dr Moody read her BSc in Biological Sciences at Teesside University, and went on to complete a PhD in Medical Sciences with Hull York Medical School, specifically focusing on the role of microRNA in chemoresistance of the asbestos-related cancer, Malignant Pleural Mesothelioma.

Previously, Dr Moody held Postdoctoral positions with the Department of Biomedical Sciences at the University of Hull and the Joint Centre for Cancer Studies with Hull York Medical School. Her initial position involved a large EU-based project investigating novel microfluidic-based platforms in the diagnosis of EGFR mutation in the peripheral blood of Non-Small Cell Lung Cancer patients. Dr Moody was then granted a small project award to further investigate the mechanisms behind chemoresistance in MPM as studied in her PhD thesis, this was followed by an additional position utilising microfluidics to maintain HNSCC and CRC tumour samples 'on-chip' for the study of novel immunotherapies and their cellular targets. 

Throughout her academic career Dr Moody has been passionate and enthusiastic supporter of student progression, and actively enjoys engaging with new and adaptive pedagogical approaches to apply from Foundation to PhD level, to enhance the student experience and build a practical knowledge base.


Dr Moody is particularly interested in thoracic malignancies, and why this group of diseases are particularly difficult to treat, often being inherently resistant to treatment, or developing resistance to specific drugs. Her research focuses upon Malignant Pleural Mesothelioma (MPM) and how the disease utilises intracellular pathways to modify treatment response.

Dr Moody is also interested in both Non-Small Cell and Small Cell lung cancer, with particular emphasis on potential repurposing of existing drugs to treat these cancers to improve progression-free survival for patients.